Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIDATE vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis, common cold, or sinusitis including nasal congestion, rhinorrhea, sneezing, and cough.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Brompheniramine: 12-34 hours (mean ~24 h), prolonged in hepatic impairment. Pseudoephedrine: 5-8 hours (p H-dependent urinary excretion; alkaline urine prolongs half-life). Dextromethorphan: 3-4 hours (extensive metabolizers) or 18-24 hours (poor metabolizers of CYP2D6).
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Brompheniramine: extensively metabolized via hepatic CYP450 (CYP2D6, CYP3A4) to desmethylbrompheniramine and other metabolites. Pseudoephedrine: partially metabolized via N-demethylation (CYP450) to norgseudoephedrine; 43-96% excreted unchanged. Dextromethorphan: primarily metabolized via CYP2D6 to dextrorphan (active), also via CYP3A4/5 to 3-methoxymorphinan.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Brompheniramine: Renal (approx. 80% as metabolites, <1% unchanged). Pseudoephedrine: Renal (70-90% unchanged, rest as metabolites). Dextromethorphan: Renal (primarily as metabolites, <1% unchanged). Biliary/fecal: Minor for all three.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
Brompheniramine: 60-80% (primarily albumin, alpha-1-acid glycoprotein). Pseudoephedrine: <10% (negligible). Dextromethorphan: 50-60% (possibly to albumin).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
Brompheniramine: 7-10 L/kg (large, due to extensive tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (moderate, distributes into body water). Dextromethorphan: 3-5 L/kg (moderate, distributed to tissues including brain).
IV: 100%; IM: >90%; Rectal: ~50% (variable).
Brompheniramine: ~70% (oral). Pseudoephedrine: 90-100% (oral). Dextromethorphan: ~10-30% (oral, due to extensive first-pass metabolism; in poor metabolizers, bioavailability higher).
No adjustment required; pharmacokinetics unchanged in renal impairment.
GFR ≥30 m L/min: No adjustment. GFR 10-29 m L/min: Administer every 6 hours; monitor for CNS effects. GFR <10 m L/min: Avoid use (risk of toxicity from pseudoephedrine and dextromethorphan accumulation).
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce frequency (e.g., every 6 hours) and monitor for CNS depression. Child-Pugh C: Avoid use (dextromethorphan metabolism reduced; brompheniramine may accumulate).
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Children 6-11 years: 1/2 tablet (brompheniramine maleate 2 mg, pseudoephedrine HCl 30 mg, dextromethorphan HBr 7.5 mg) orally every 4 hours, not to exceed 4 doses in 24 hours. Children 2-5 years: Not recommended (safety and efficacy not established). Children <2 years: Contraindicated (risk of respiratory depression).
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
Elderly >65 years: Initiate at lowest effective dose (e.g., 1/2 tablet) every 6-8 hours due to increased anticholinergic effects, hypotension, and CNS excitation. Maximum: 2 tablets in 24 hours. Monitor for confusion, urinary retention, and elevated blood pressure.
None
None.
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias, especially in patients with pre-existing heart disease or hyperthyroidism.,CNS depression: avoid concurrent use with alcohol or other sedatives; may impair mental/physical abilities.,Serotonin syndrome: risk with concomitant serotonergic drugs including MAOIs, SSRIs, SNRIs, triptans, linezolid, methylene blue.,QT prolongation: caution with drugs that prolong QT interval or predisposing conditions (e.g., electrolyte abnormalities, bradycardia).,Anticholinergic effects: caution in patients with glaucoma, prostatic hypertrophy, urinary retention, or asthma.,Inhibition of CYP2D6: dextromethorphan may increase levels of CYP2D6 substrates (e.g., TCAs, antipsychotics).
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
Hypersensitivity to any component,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis),Severe hypertension or coronary artery disease,Narrow-angle glaucoma,Urinary retention,During or immediately after treatment with serotonergic drugs (risk of serotonin syndrome)
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
Avoid alcohol, which may potentiate CNS depression. Limit caffeine intake (coffee, tea, cola) as pseudoephedrine may increase stimulant effects. High-tyramine foods (e.g., aged cheese, cured meats, fermented products) may cause hypertensive crisis if combined with MAOIs, but this combination is contraindicated. No other significant food interactions.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastroschisis and hemifacial microsomia with first-trimester use; vasoconstriction may reduce uteroplacental blood flow in third trimester. Dextromethorphan: No human teratogenicity data; animal studies show no fetal harm at therapeutic doses. Overall, combination is not recommended in first trimester; avoid in third trimester due to pseudoephedrine effects.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Brompheniramine: excreted in breast milk in small amounts; may cause infant irritability or drowsiness. Pseudoephedrine: concentrated in breast milk (M/P ratio ~3.0); may reduce milk production. Dextromethorphan: likely excreted in breast milk but no data on infant levels. Avoid during breastfeeding due to potential infant CNS effects and reduced milk supply.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
No specific dose adjustments studied for combination in pregnancy. Due to increased plasma volume and clearance, standard adult doses may be less effective; however, avoid use in pregnancy due to risks. No PK studies available.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
Do not use in children under 6 years due to risk of respiratory depression from dextromethorphan. Avoid in patients with hypertension or coronary artery disease due to pseudoephedrine. Brompheniramine has pronounced anticholinergic effects; use cautiously in elderly or those with glaucoma, urinary retention, or BPH. For severe cough, dextromethorphan efficacy is limited; consider if nonproductive cough is disruptive. Maximum duration of treatment is 7 days; prolonged use may lead to rebound congestion and dependence.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
Do not take more than 6 doses in 24 hours. Do not exceed 7 days of use without consulting a doctor.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness.,Do not use if you have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.,Stop use and ask a doctor if symptoms do not improve within 7 days, are accompanied by fever, or if cough persists with headache, rash, or persistent headache.,Take with a full glass of water. May cause drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,For the decongestant effect, take the last dose of the day several hours before bedtime to minimize insomnia.,Shake suspension well before use. Use only the dosing device provided.
No interactions on record
"Brompheniramine, a first-generation antihistamine, may inhibit the hepatic metabolism of sulfamethoxazole, a sulfonamide antibiotic, via competitive inhibition of cytochrome P450 enzymes, particularly CYP2C9. This results in elevated plasma concentrations of sulfamethoxazole, potentially increasing the risk of dose-dependent adverse effects such as hypersensitivity reactions, crystalluria, and hematologic toxicity (e.g., agranulocytosis). Clinically, patients may present with prolonged or intensified drug effects, including increased bone marrow suppression and renal impairment, especially in those with pre-existing hepatic or renal dysfunction."
"Dextropropoxyphene, an opioid analgesic, and brompheniramine, a first-generation antihistamine with anticholinergic properties, can synergistically depress the central nervous system (CNS) and respiratory centers. This interaction increases the risk of profound sedation, respiratory depression, coma, and death, particularly in elderly patients or those with pre-existing respiratory or hepatic impairment. Concurrent use also amplifies anticholinergic adverse effects such as urinary retention, constipation, and cognitive dysfunction."
"Brompheniramine, a first-generation antihistamine with significant central nervous system (CNS) depressant properties, can potentiate the CNS depressant effects of brimonidine, an alpha-2 adrenergic agonist used for ocular hypertension and glaucoma. This interaction leads to additive sedation, drowsiness, and dizziness, which may impair cognitive and motor function, increasing the risk of falls and accidents. Severe cases could result in excessive CNS depression, including somnolence and respiratory depression, particularly in elderly patients or those with compromised hepatic function."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIDATE vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, answered by our medical review team.
AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is a Sympathomimetic that works by Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIDATE and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. The standard adult dose of BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is: Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIDATE and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is classified as Category A/B. Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.